Last updated 2026-07-27
- Went public on NASDAQ (ORGS), Aug 2011
- Raised $30M IPO led by Metalmark Capital, Nov 2022
- Raised $34.6M grant led by Greek government, Nov 2021
Total raised
$92.9M
Last: Debt Financing 2025-01
Stage
Public
Founded
2008
Headcount
77
HQ
Germantown, United States
Sector
Health Tech & Life Sciences
About
Orgenesis is a global biotech company committed to unlocking the potential of cell and gene therapies (CGTs) in an affordable and accessible format. The company focuses on autologous therapies, with processes and systems developed for each therapy using a closed and automated approach that is validated for compliant production near the patient for treatment at the point of care (POCare). Orgenesis aims to provide a rapid, globally harmonized pathway for these therapies to reach and treat large numbers of patients at lowered costs through efficient, scalable, and decentralized production.
Funding history · 9 rounds · $92.9M total
11 events/rounds · $92.9M Total Funding: $13.3M in Private Equity, $35.0M in Public Equity, $5.0M in Debt
Sep 2025
★ Alpha Prosperity Fund SPCTheracell Laboratories IKE
Jan 2025
★ Williamsburg Venture Holdings, LLC
Apr 2024
★ Accredited investors★ healthcare professionals★ sophisticated, long-term healthcare professionals
Aug 2023
May 2023
★ Metalmark Capital
Nov 2022
★ Metalmark Capital
Jan 2022
★ State of Maryland★ European Innovation Council Pathfinder Challenge Program
Nov 2021
★ Greek government
Dec 2015
★ Accredited investors
Headcount over time
77 employees (2026-09) · 1 point
Offices
Germantown, United States · HQ / main office
Q&A
- What was Orgenesis's most recent funding round?
- In January 2025, Orgenesis secured $5,000,000 in Debt Financing from Williamsburg Venture Holdings, LLC.
- What was the amount of the Convertible Debt round Orgenesis received in 2025?
- In 2025, Orgenesis received $1,000,000 in Convertible Debt from Alpha Prosperity Fund SPC.
- What was the most recent Public Offering for Orgenesis?
- In 2024, Orgenesis had a Public Offering with Nathan Low & 5 more investors.
- What was the amount of the Public Offering Orgenesis completed in October 2023?
- In October 2023, Orgenesis completed a Public Offering of $5,000,000 with Metalmark Capital Partners.
- What was the amount of the Convertible Debt round Orgenesis received in November 2022?
- In November 2022, Orgenesis received $50,000,000 in Convertible Debt from Yehuda Nir and Metalmark Capital.
- When did Orgenesis commence trading on the OTCQX Best Market?
- Orgenesis commenced trading on the OTCQX® Best Market on October 21, 2024.
- What was a significant acquisition made by Orgenesis in early 2024?
- In January 2024, Orgenesis acquired control of Octomera, aiming to progress its decentralized immuno-oncology portfolio to the clinic.
- What strategic partnership did Orgenesis announce in August 2024?
- In August 2024, Orgenesis announced a strategic partnership with Harley Street Healthcare Group to launch a global longevity & wellness initiative.
- What was the outcome of the real-world study for Orgenesis's ORG-101 CAR-T therapy announced in August 2024?
- In August 2024, Orgenesis announced positive results from a real-world study of ORG-101 CAR-T therapy in patients with CD19+ Acute Lymphoblastic Leukemia.
Team · 16
Sarah Ferber
Founder · CTO, Chief Tech/Sci/R&D Officer
Vered Caplan
Chief Executive Officer & President, Chairperson of the Board
Victor Miller
Chief Financial Officer
Heiko von der Leyen
Medical Director
Douglas Karriker
Director of Finance/CFO
Gerhard Bauer
Corporate Officer/Principal
Yaron Adler
Independent Director
G. Alexander Fleming
Member of Advisory Board
Jay S. Skyler
Member of Advisory Board
Lorenzo Piemonti
Member of Advisory Board
Bala S. Manian
Member of Advisory Board
Stephen Minger
Member of Advisory Board
Joseph Press
Member of Advisory Board
Micha Drukker
Member of Advisory Board
Itzhak Vider
Independent Director
Adam Pelavin
Independent Director
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCells
Target customers
Healthcare & Life SciencesHealthcareLaboratoriesProvidersLife SciencesPharmaceuticalsBiotechnology
Business model
B2B
Highlights
1 Patents
Tags
therapeuticscell-therapydiabetesmedical-technologiesbiotechnologylaboratoriespharma-companiesimmunotherapyhospitalsacademiaoncologyregenerative-medicinetreatmentsbioconvergence
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | orgenesis.com |
|---|---|
| linkedin.com/company/6112356 | |
| facebook.com/Orgenesis-Inc-101879208270597 | |
| YouTube | youtube.com/channel/UCMyvWvSUuJt0Hvmis-EIrhg |
Identifiers & details
| Legal name | Orgenesis Inc. |
|---|---|
| Founded | 2008-6 |
| Employees (exact) | 77 |
| Offices | Germantown |
| Market cap | $776K |
| Status reason | Public on NASDAQ on Mar, 2018; |
Acquisitions & public offerings
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| IPO | 2011-08 | NASDAQ | ORGS | |
| Underwritten Public Offering | 2023-10 | NASDAQ | ORGS |
Radar intelligence
Patents
| EPO | 33 |
|---|
Publications (Crossref)
| Works | 10 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 514678937 |
|---|---|
| Status | פעילה/בפירוק - הליך פשרה או הסדר/פירוק זמני |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2011-10-11 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2024 |
| Active charges / liens | 0 |
| Registry events | 0 |
| Registered address | פנחס ספיר 8 נס ציונה |